Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Taormina

Internal Medicine Shelby Township, MI Doctor of Osteopathy

NPI 1134111065 CMS profile 142177

50505 Schoenherr Rd, Suite 300, Shelby Township, MI 48315

Open in the dashboard

General payments

$9,186

565 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Steven Taormina of Shelby Township, MI is reported in the CMS Open Payments database as having received $9,186 across 565 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,957 111
2024 General $2,139 116
2023 General $1,593 99
2022 General $1,739 115
2021 General $695 41
2020 General $247 17
2019 General $816 66

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Taormina
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Steven Taormina were reported at $1,957. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Steven Taormina Internal Medicine median Middle half National median
2019 $816 $159 $48–$570 $163
2020 $247 $119 $33–$402 $114
2021 $695 $135 $37–$521 $132
2022 $1,739 $141 $42–$496 $149
2023 $1,593 $149 $45–$519 $160
2024 $2,139 $154 $47–$537 $164
2025 $1,957 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,003 58 payments
  2. Novo Nordisk Inc $920 57 payments
  3. AbbVie, Inc. $887 65 payments
  4. Lilly USA, LLC $851 63 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $764 44 payments
  6. Abbott Laboratories $656 29 payments
  7. Amgen Inc. $591 41 payments
  8. Pfizer Inc. $570 40 payments
  9. Exact Sciences Corporation $480 24 payments
  10. Merck Sharp & Dohme Corporation $284 22 payments
  11. Other $2,180 122 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,186 565 payments
Products named General payments · program years 2019–2025
  1. FreeStyle Libre 3 $638 28 payments
  2. FARXIGA $531 29 payments
  3. UBRELVY $487 37 payments
  4. MOUNJARO $442 28 payments
  5. Ozempic $424 29 payments
  6. RYBELSUS $400 28 payments
  7. BREZTRI $384 19 payments
  8. JARDIANCE $364 32 payments
  9. Cologuard Collection Kit $346 17 payments
  10. QULIPTA $343 23 payments
  11. Other $8,860 570 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 117 drugs

Part D claims

6,041

Median for Internal Medicine: 777

Drug cost

$561,266

Median for Internal Medicine: $73,373

Branded share of claims

22.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 57 $83,097
Jardiance Empagliflozin Brand 59 $67,795
Mounjaro Tirzepatide Brand 61 $66,199
Eliquis Apixaban Brand 64 $65,162
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 71 $48,329
Farxiga Dapagliflozin Propanediol Brand 41 $38,159
Januvia Sitagliptin Phosphate Brand 19 $19,765
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 31 $15,705
Xarelto Rivaroxaban Brand 14 $12,765
Myrbetriq Mirabegron Brand 13 $11,824

The 10 drugs with the highest cost, of 117 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$44,181

Of which drugs: $11,850

Medicare patients

182

Average age 76

Services billed

2,649

97 women, 85 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Chronic kidney disease 34%
Ischemic heart disease 31%
Diabetes 27%
Depression 26%
Cancer 17%
Heart failure 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 38 38 $2,787

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BREZTRI
  • AstraZeneca Pharmaceuticals LP $170
$170 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $81
  • Lilly USA, LLC $56
$137 59 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $111
$111 41 —
MOUNJARO
  • Lilly USA, LLC $99
$99 61 —
UBRELVY
  • AbbVie, Inc. $84
$84 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

565 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record